Elevian, AI company Insilico partner to find anti-aging candidates in GDF11 pathway

Elevian Inc. (Allston, Mass.) partnered with AI company Insilico Medicine Inc. (Baltimore, Md.) to use deep-learning technology to discover small molecules that target the GDF11 pathway to treat age-related diseases.

Insilico will apply its generative adversarial networks and reinforcement learning technologies to biological and structural target data from Elevian to identify small molecules that produce the intended biological actions. Insilico will then narrow down a selection of de novo compound candidates, which will be synthesized by WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359). Financial terms were not disclosed...